+5.42%
Today
Loading 1D prices…
Company profile
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Miami, FL, United States
CIK
1904286
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| RMTIRockwell Medical Inc. Common Stock | $31.9M | $69.3M | -7.67% | -$0.15 | +1.41% | Buy |
| ABVCABVC BioPharma Inc. Common Stock | $30.7M | $0.00 | — | -$0.39 | +6.48% | Unrated |
| CPHIChina Pharma Holdings Inc. Common Stock | $30.6M | $4.1M | -76.91% | -$0.74 | -0.10% | Unrated |
| FLNAFilana Therapeutics Inc. Common Stock | $34.8M | $0.00 | — | -$1.88 | +5.88% | Buy |
| BYSIBeyondSpring Inc. Ordinary Shares | $29.1M | $0.00 | — | -$0.02 | 0.00% | Unrated |